Wright State Physicians, Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$71,996	7
2024	Research	$15,544	2
2023	Research	$6,786	1
2022	Research	$165,389	6
2021	Research	$85,693	4

Breakdown

Who paid Research payments · program years 2021–2025

Ucb SA $216,988 10 payments
E.R. Squibb & Sons, L.L.C. $57,551 5 payments
Novartis Pharmaceuticals Corporation $39,726 4 payments
Amgen Inc. $31,142 1 payment

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $158,471 6 payments
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $56,843 3 payments
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis $44,503 2 payments
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup $37,939 1 payment
P3 switching study PK; plaque psoriasis $31,142 1 payment
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $13,049 3 payments
A Multicenter, Open-Label Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Pubertal Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa $1,675 1 payment
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R $1,334 2 payments
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $454 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.